Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Pancreatic Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Castration-Resistant Prostate Carcinoma|Clinical Stage III Gastric Cancer AJCC v8|Clinical Stage IV Gastric Cancer AJCC v8|HER2-Positive Breast Carcinoma|Locally Advanced Breast Carcinoma|Locally Advanced Gastric Carcinoma|Locally Advanced Malignant Solid Neoplasm|Locally Advanced Ovarian Carcinoma|Locally Advanced Pancreatic Carcinoma|Locally Advanced Prostate Carcinoma|Metastatic Breast Carcinoma|Metastatic Gastric Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Ovarian Carcinoma|Metastatic Pancreatic Carcinoma|Metastatic Prostate Carcinoma|Platinum-Sensitive Ovarian Carcinoma|Stage II Pancreatic Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage III Prostate Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8
Interventions: PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|DRUG: Talazoparib
Sponsor: National Cancer Institute (NCI)